7β-hydroxy-16α-fluoroandrost-5-ene-17-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 7β-hydroxy-16α-fluoroandrost-5-ene-17-one
• 英文别名: 16α-fluoro-7β-hydroxy-5-androsten-17-one；(7R,8R,9S,10R,13S,14S,16R)-16-fluoro-7-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
• 化学式: C₁₉H₂₇FO₂
• 分子量: 306.421
• InChiKey: GIYRMQWUECCQBF-IEYLFTFUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。
• Compounds useful for treating hypertriglyceridemia
  申请人：——

  公开号：US20040019026A1

  公开（公告）日：2004-01-29

  The present invention is directed to a method for treating a patient having hypertriglyceridemia comprising administering thereto a compound of the formula: 1

  本发明涉及一种治疗高甘油三酯血症患者的方法，包括向其投药式为1的化合物。
• 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof
  申请人：——

  公开号：US20040034003A1

  公开（公告）日：2004-02-19

  The present invention relates to 7-hydroxy-16&agr;-fluoro-5-androsten-17-one and 7-hydroxy-16&agr;-fluoro-5-androstan-17-one derivatives and their use.

  本发明涉及7-羟基-16α-氟-5-雄烯-17-酮和7-羟基-16α-氟-5-雄甾烷-17-酮衍生物及其用途。
• Compositions and treatment methods
  申请人：Ahlem N. Clarence

  公开号：US20060079492A1

  公开（公告）日：2006-04-13

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄甾烷可用于治疗方法。
• Drug Screen and Treatment Method
  申请人：Flores-Riveros Jaime

  公开号：US20080221074A1

  公开（公告）日：2008-09-11

  The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one.

  本发明涉及用于治疗特定临床疾病，如高血糖和2型糖尿病的化合物的鉴定或表征方法。可以在这些方法中使用的化合物包括4α-氟-17α-乙炔基雄烯-5-烯-3β，7β，17β-三醇，4α-氟-17α-乙炔基雄烯-5-烯-3β，7α，17β-三醇，4α-氟-17α-乙炔基雄烯-5-烯-3α，7β，17β-三醇和4α-氟-17α-乙炔基雄烯-5-烯-3β，17β-三醇-7-酮。